SOUTH
SAN FRANCISCO, Calif., Feb. 25,
2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
(Nasdaq: RIGL) today announced that it will report its fourth
quarter and full year 2024 financial results after market close on
Tuesday, March 4, 2025. Rigel
senior management will follow the announcement with a live
conference call and webcast at 4:30 p.m.
Eastern Time (1:30 p.m. Pacific
Time) to discuss the financial results and give an update on
the business.
Participants can access the live conference call by dialing
877-407-3088 (domestic) or 201-389-0927 (international). The
conference call and accompanying slides will also be webcast live
and can be accessed from the Investor Relations section of the
company's website at www.rigel.com. The webcast will be
archived and available for replay for 90 days after the call via
the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
is a biotechnology company dedicated to discovering, developing and
providing novel therapies that significantly improve the lives of
patients with hematologic disorders and cancer. Founded in 1996,
Rigel is based in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products,
visit www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David
Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2024-financial-results-and-business-update-302384250.html
SOURCE Rigel Pharmaceuticals, Inc.
